Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis

Abstract

The economic impact of psychiatric relapse and recidivism among patients with schizophrenia is substantial from the state government perspective. This general model can be made state-specific by utilizing local criminal justice data sources.

Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement

“…Patients with serious mental illnesses who receive antipsychotic treatment after hospitalization or incarceration have a reduced risk of arrest and thus have lower total cumulative costs 4,5 . To our knowledge, there are no direct comparisons (i.e., head-to-head trials) that address the cost effectiveness of long acting atypical agents versus oral antipsychotics in vulnerable populations, such as persons with criminal justice system contact(s).…”

“…Patients with serious mental illness have a high risk of incarceration and the total cost of care for incarcerated patients with serious mental illness is significantly greater than for non-incarcerated patients with serious mental illness 4 . Psychiatric relapse and recidivism are both common and costly among patients with schizophrenia after they are released from incarceration 5 .…”

Personalizing Antipsychotic Treatment of Schizophrenia: Monitoring Plasma Levels for Improved Treatment Decisions

“…Conversely, controlling psychotic symptoms quickly and decisively shortens acute psychotic episodes, avoiding immense patient and family suffering. 25,26 In first-episode schizophrenia, longer duration of untreated psychosis can significantly impact short-and long-term prognosis. [27][28][29][30][31] In chronic schizophrenia, each relapse contributes additional illness-related disability and complicates ensuing treatment efforts.…”

Cost-Effectiveness of Individualized Occupational Therapy for Schizophrenia: Results from a Two-Year Randomized Controlled Trial

“…Schizophrenia is associated with frequent rehospitalization during its clinical course, with considerable economic burden [14][15][16][17][18][19][20]. Hospitalization has been identified as a significant cost driver [21,22]. Estimates of the annual economic burden of schizophrenia in Japan in 2008 were JPY 2.77 trillion (US$ 23.8 billion) for total costs, while the total cost per patient was JPY 3 538 751 million (US$ 30 298) [18].…”